

## BELLADONNA AND OPIUM SUPPOSITORIES (BANDO SUPPRETTES) [C-II]



### BELLADONNA AND OPIUM SUPPOSITORIES (BANDO SUPPRETTES) [C-II]

**USES:** \*Bladder spasms; mod/severe pain\*

**ACTION:** Antispasmodic, analgesic

**DOSE:** 1 suppository PR q6h PRN

**CAUTION:** [C, ?]

**CI:** Glaucoma, respiratory depression

**DISP:** 15A = 30 mg opium/16.2 mg belladonna extract; 16A = 60 mg opium/16.2 mg belladonna extract

**SE:** Anticholinergic (eg, sedation, urinary retention, constipation)



### BENAZEPRIL (LOTENSIN)

**USES:** \*Hypertension,\* diabetic nephropathy, CHF

**ACTION:** ACE inhibitor

**DOSE:** 10–80 mg/d PO

**CAUTION:** [C (1st trimester), D (2nd and 3rd trimesters), +]

**CI:** Angioedema, history of edema, bilateral RAS

**DISP:** Tablets 5, 10, 20, 40 mg

**SE:** Symptomatic ↓ BP w/diuretics; dizziness, headache, ↑ K<sup>+</sup>, nonproductive cough



### BETHANECHOL (URECHOLINE, DUVOID, OTHERS)

**USES:** \*Acute postop/postpartum nonobstructive urinary retention; neurogenic bladder with retention\*

**ACTION:** Stimulates cholinergic smooth muscle in bladder and GI tract

**DOSE:**

**Adults:** Initial 5–10 mg then repeat hourly until response or 50 mg, typical 10–50 mg t.i.d.–q.i.d., 200 mg/d max t.i.d.–q.i.d.; 2.5–5 mg SQ t.i.d.–q.i.d. and PRN.

**Peds:** 0.3–0.6 mg/kg/24 hr PO divided t.i.d.–q.i.d. or 0.15–2 mg/kg/d SQ divided 3–4 doses; take on empty stomach

**CAUTION:** [C, –]

**CI:** BOO, PUD, epilepsy, hyperthyroidism, bradycardia, COPD, AV conduction defects, Parkinsonism, ↓ BP, vasomotor instability

**DISP:** Tablets 5, 10, 25, 50 mg; injectable 5 mg/mL

**SE:** Abdominal cramps, diarrhea, salivation, ↓ BP

**NOTES:** Do not use IM/IV



### BEVACIZUMAB (AVASTIN)

**WARNING:** Associated with GI perforation, wound dehiscence, and fatal hemorrhage, hemoptysis and GI bleeding

**USES:** \*Breast, lung, colon, and rectum cancers, glioblastoma multiforme, with interferon alpha in metastatic RCC\*

**ACTION:** Vascular endothelial GF (VEGF) inhibitor, recombinant humanized monoclonal antibody

**DOSE:** RCC: 10 mg/kg IV infusion every 2 wk in combination with interferon alfa 2b (Roferon-A) 9 million units 3 times a week

**CAUTION:** [C, –] Do not use w/in 28 d of surgery; D/C with serious adverse effects

**DISP:** 100 mg/4 mL, 400 mg/16 mL vials

**SE:** Wound dehiscence, GI perforation, tracheoesophageal fistula, arterial thrombosis, hemoptysis, hemorrhage, hypertension, proteinuria, CHF, infections, diarrhea, leukopenia

**NOTES:** Monitor for—BP & proteinuria; Roferon-A discontinued in US in 2007



### BICALUTAMIDE (CASODEX, GENERIC)

**USES:** \*Advanced prostate cancer w/LHRH agonists (eg, leuprolide, goserelin\*)

**ACTION:** Nonsteroidal antiandrogen

**DOSE:** 50 mg/d

**CAUTION:** [Not indicated in women X, ?]

**CI:** Women

**DISP:** Capsules 50 mg

**SE:** Hot flashes, loss of libido, impotence, D/N/V, gynecomastia, and LFT elevation



### BLEOMYCIN SULFATE (BLENOXANE)

**USES:** \*Testis cancer; Hodgkin disease and NHLs; cutaneous lymphomas; and SCC (head and neck, larynx, cervix, skin, penis); malignant pleural effusion sclerosing agent\*

**ACTION:** Induces DNA breakage (scission)

**DOSE:** Typical (per protocols) 0.25–0.5 U/kg (10–20 units/m<sup>2</sup>) 1–2 times/week; IV infusion: 15 U/m<sup>2</sup> × 4 days; ↓ w/renal impairment

**CAUTION:** [D, ?]

**CI:** Severe pulmonary disease (pulmonary fibrosis)

**DISP:** Powder (injectable) 15, 30 U

**SE:** Hyperpigmentation and allergy (rash to anaphylaxis); fever in 50%; lung toxicity (idiosyncratic and dose-related); pneumonitis w/fibrosis; Raynaud phenomenon, N/V

**NOTES:** Test dose is 1 U, especially in lymphoma patients; lung toxicity w/total dose >400 U or single dose >30 U; avoid high FiO<sub>2</sub> in general anesthesia to ↓ toxicity



### BOTULINUM TOXIN TYPE A (BOTOX, BOTOX COSMETIC, MYOBLOC, DYSPORT)

**WARNING:** Distant spread of toxin is possible.

**USES:** \*Glabellar lines (cosmetic), blepharospasm, cervical dystonia, axillary hyperhidrosis, strabismus\*, overactive bladder

**ACTION:** Neurotoxicity, ↓ acetylcholine release from nerve endings, ↓ neuromuscular transmission; denervates sweat glands and muscles

**DOSE:**

**Adults:** *Glabellar lines (cosmetic):* 0.1 mL IM × 5 sites q3–4mo; *Blepharospasm:* 1.25–2.5 U IM/site q3mo; max 200 U/30 days cumulative dose; *Cervical dystonia* 198–300 U IM divided <100 U into sternocleidomastoid

**Peds:** *Blepharospasm:* > 12 yr: See adult. *Cervical dystonia:* > 16 yr: 198–300 U IM divided among affected muscles; use <100 U in sternocleidomastoid

**CAUTION:** [C, ?]; different products have different dosing units; w/neurologic disease; do not exceed dosing recommended; caution sedentary patient to resume activity slowly after injection; aminoglycosides and nondepolarizing muscle blockers may ↑ effects; risk for distant spread at the time of injection

**CI:** Hypersensitivity to components, injection site infection

**DISP:** 100 U injectable powder; reconstitute in 10 mL NS (10 U/mL)

**SE:** Anaphylaxis, erythema multiforme, dysphagia, dyspnea, syncope, headache, narrow-angle glaucoma, injection site pain, botulism poisoning (muscle weakness, hoarseness or trouble talking, trouble saying words clearly, loss of bladder control, trouble breathing or swallowing, double vision, blurred vision, or drooping eyelids)

**NOTES:** Fatalities with distant spread mostly in children and not during cosmetic use. Not FDA approved in urinary tract; typical bladder regimen reported 10–30 injections of 10U/1 mL/site (posterior wall in midline, right and left lateral walls and dome); trigone is spared



### BUMETANIDE (BUMEX)

**USES:** \*Edema from CHF, hepatic cirrhosis, and renal disease\*

**ACTION:** Loop diuretic; ↓ reabsorption of Na<sup>+</sup> and Cl<sup>-</sup>, in ascending loop of Henle and distal tubule

**DOSE:**

**Adults:** 0.5–2 mg/d PO; 0.5–1 mg IV/IM q8–24h (max 10 mg/d).

**Peds:** 0.015–0.1 mg/kg PO q6–24h (max 10 mg/d)

**CAUTION:** [D, ?]

**CI:** Anuria, hepatic coma, severe electrolyte depletion

**DISP:** Tablets 0.5, 1, 2 mg; injectable 0.25 mg/mL

**SE:** ↓ K<sup>+</sup>, ↓ Na<sup>+</sup>, ↑ Cr, ↑ uric acid, dizziness, ototoxicity

**NOTES:** Monitor fluid and electrolytes



### BUTABARBITAL, HYOSCYAMINE HYDROBROMIDE, PHENAZOPYRIDINE (PYRIDIUM PLUS)

**USES:** \*Relieve urinary tract pain w/UTI, procedures, trauma\*

**ACTION:** Phenazopyridine (topical anesthetic), hyoscyamine (parasympatholytic, ↓ spasm), and butabarbital (sedative)

**DOSE:** 1 PO q.i.d., p.c. and h.s.; w/antibiotic for UTI, 2 days max

**CAUTION:** [C, ?]

**DISP:** Tablet butabarbital/hyoscyamine/phenazopyridine 15 mg/0.3 mg/150 mg